Recent chatter on X about AbbVie (ABBV) has been notably active, driven by the company's latest clinical trial results and stock price movements. Many users are discussing the positive topline results from a Phase 3 trial for upadacitinib (Rinvoq) in treating alopecia areata, viewing it as a potential boost to AbbVie's already strong portfolio. The stock's recent breakout to new highs has also sparked excitement, with some pointing to robust sales growth from key drugs like Skyrizi and Rinvoq as a driving force.
Additionally, AbbVie's strategic moves, such as the acquisition of Capstan Therapeutics, have fueled conversations about the company's long-term growth prospects in the biopharmaceutical space. Posts on X reflect a sense of optimism, with several users highlighting the firm's record quarterly revenues and raised sales forecasts as signs of sustained momentum. The discussion underscores a keen interest in how these developments might shape AbbVie's future trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
AbbVie Congressional Stock Trading
Members of Congress have traded $ABBV stock 18 times in the past 6 months. Of those trades, 12 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 3 times. They made 3 purchases worth up to $45,000 on 08/04, 05/05, 03/17 and 0 sales.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 2 purchases worth up to $30,000 on 07/22, 06/17 and 1 sale worth up to $15,000 on 07/22.
- REPRESENTATIVE RITCHIE TORRES sold up to $15,000 on 07/11.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 4 times. They made 3 purchases worth up to $45,000 on 05/22, 04/03, 04/01 and 1 sale worth up to $15,000 on 04/17.
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 3 times. They made 2 purchases worth up to $30,000 on 05/15, 02/25 and 1 sale worth up to $15,000 on 04/08.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 1 purchase worth up to $100,000 on 02/24 and 1 sale worth up to $100,000 on 04/17.
- REPRESENTATIVE JARED MOSKOWITZ purchased up to $15,000 on 04/07.
- REPRESENTATIVE DWIGHT EVANS sold up to $15,000 on 04/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AbbVie Insider Trading Activity
AbbVie insiders have traded $ABBV stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- AZITA SALEKI-GERHARDT (EVP, CHIEF OPERATIONS OFFICER) sold 42,370 shares for an estimated $8,407,055
- TIMOTHY J. RICHMOND (EVP, CHIEF HR OFFICER) has made 0 purchases and 6 sales selling 29,917 shares for an estimated $6,070,036.
- KEVIN K BUCKBEE (SVP, CONTROLLER) has made 0 purchases and 2 sales selling 18,944 shares for an estimated $3,853,372.
- SCOTT T REENTS (EVP, CHIEF FINANCIAL OFFICER) sold 17,644 shares for an estimated $3,746,526
- NICHOLAS DONOGHOE (EVP, CHIEF BUS/STRAT OFFICER) has made 0 purchases and 2 sales selling 13,295 shares for an estimated $2,639,252.
- PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 2 sales selling 5,778 shares for an estimated $1,143,452.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AbbVie Hedge Fund Activity
We have seen 1,823 institutional investors add shares of AbbVie stock to their portfolio, and 1,726 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GAMMA INVESTING LLC removed 10,182,211 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $1,890,022,005
- CAPITAL WORLD INVESTORS removed 9,691,073 shares (-59.9%) from their portfolio in Q2 2025, for an estimated $1,798,856,970
- CAPITAL RESEARCH GLOBAL INVESTORS removed 8,242,435 shares (-24.6%) from their portfolio in Q2 2025, for an estimated $1,529,960,784
- CAPITAL INTERNATIONAL INVESTORS removed 6,885,308 shares (-33.5%) from their portfolio in Q2 2025, for an estimated $1,278,050,870
- ASSENAGON ASSET MANAGEMENT S.A. added 3,666,521 shares (+550.9%) to their portfolio in Q2 2025, for an estimated $680,579,628
- VANGUARD GROUP INC added 3,380,842 shares (+1.9%) to their portfolio in Q2 2025, for an estimated $627,551,892
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC added 3,134,454 shares (+inf%) to their portfolio in Q2 2025, for an estimated $581,817,351
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AbbVie Government Contracts
We have seen $487,590 of award payments to $ABBV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- IMPLANTS: $36,934
- IMPLANT: $35,788
- 4567253744!NATRELLE TE SMOOTH 133S-SV-13-T: $33,629
- IMPLANTS: $29,604
- BREAST IMPLANTS: $14,187
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AbbVie Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 08/12/2025
- Guggenheim issued a "Buy" rating on 08/01/2025
- Raymond James issued a "Outperform" rating on 04/28/2025
- Evercore ISI Group issued a "Outperform" rating on 04/28/2025
- Morgan Stanley issued a "Overweight" rating on 04/28/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/22/2025
- Wells Fargo issued a "Overweight" rating on 03/05/2025
To track analyst ratings and price targets for AbbVie, check out Quiver Quantitative's $ABBV forecast page.
AbbVie Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 10 analysts offer price targets for $ABBV in the last 6 months, with a median target of $225.0.
Here are some recent targets:
- David Amsellem from Piper Sandler set a target price of $231.0 on 08/12/2025
- Gary Nachman from Raymond James set a target price of $236.0 on 08/01/2025
- Terence Flynn from Morgan Stanley set a target price of $255.0 on 08/01/2025
- Vamil Divan from Guggenheim set a target price of $227.0 on 08/01/2025
- Geoff Meacham from Citigroup set a target price of $205.0 on 05/14/2025
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $205.0 on 04/28/2025
- Carter Gould from Cantor Fitzgerald set a target price of $210.0 on 04/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
